secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001193125-26-030561
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.
- Phase 1b/2 trial data show CD47 expression is predictive of evorpacept response in HER2+ metastatic breast cancer.
- In 9 confirmed HER2+ patients, cORR was 56% (5/9) with median PFS of 7.4 months (prior SABCS2024 data).
- Full biomarker analysis submitted for presentation at an upcoming scientific conference.
- Results align with ASPEN-06 gastric cancer trial, strengthening confidence in ongoing ASPEN-09-Breast Phase 2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/0001193125-26-030561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/d68428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-030561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer